Abcam, ab282037, Anti-SARS-CoV-2 Spike RBD antibody [Abcam 2] - Human IgG1 (Chimeric)

Size: 20µL / 100µL / 1mL
Human Recombinant Monoclonal SPIKE antibody. Suitable for ChIP, I-ELISA and reacts with SARS-CoV-2, Recombinant fragment - SARS-CoV-2 samples.
Key facts
Host species:Human,
Clonality:Monoclonal,
Clone number:Abcam 2,
Isotype:IgG1,
Light chain type:kappa,
Carrier free:No,
Reacts with:SARS-CoV-2,
Applications:ChIP, I-ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab282037 is a human monoclonal chimeric antibody.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The SARS-CoV-2 Spike RBD also known commonly as the Receptor Binding Domain of the spike protein plays an important role in viral entry into host cells. This domain has a mass of approximately 21 kDa. It is located on the surface of the virus and facilitates binding to the host cell receptor primarily ACE2 which permits viral entry and replication. The Spike RBD is also a target for neutralizing antibodies which are essential in immune response against the virus. The domain displays various mutations particularly in variants of concern such as Omicron which can affect binding efficiency and immune evasion.
Biological function summary
The SARS-CoV-2 Spike RBD interacts directly with the host ACE2 receptor to mediate entry of the virus into host cells. This interaction is necessary for the virus to fuse with the host cell membrane which allows viral RNA to enter the host cell and begin replication. The Spike protein of which the RBD is a part forms a trimeric complex on the virus surface that is important for host interaction. Variations in the Spike RBD such as mutations like Arg319-Phe541 have significant impacts on the binding affinity to ACE2 and the effectiveness of vaccine-elicited antibodies.
Pathways
The Spike RBD of SARS-CoV-2 is vital in the entry pathway of the virus into the host cell. It is prominently involved in the ACE2-mediated signaling pathway with ACE2 playing the key role as the cellular receptor. This pathway is integral to the pathogenesis of COVID-19. Additionally the presence of the virus in host cells can trigger inflammatory pathways via infection-induced signaling cascades which can lead to exacerbated immune responses.
The SARS-CoV-2 Spike RBD is inherently linked to COVID-19 pathogenesis. Variants such as Omicron have alterations within the RBD that may confer increased transmissibility and resistance to neutralizing antibodies. These mutations can influence disease severity and vaccine effectiveness. The interaction between the Spike RBD and ACE2 receptor underlies the symptomatic manifestations of COVID-19 including respiratory distress and systemic inflammation. The emergence of RBD-targeted therapeutics and vaccines addresses its critical role in infection aiming to block the binding and prevent disease progression.